Search Results - Vivanco, Igor
- Showing 1 - 20 results of 23
- Go to Next Page
-
1
-
2
-
3
-
4
-
5
IQGAP1 controls tight junction formation through differential regulation of claudin recruitment by Tanos, Barbara E., Perez Bay, Andres E., Salvarezza, Susana, Vivanco, Igor, Mellinghoff, Ingo, Osman, Mahasin, Sacks, David B., Rodriguez-Boulan, Enrique
Published 2015Text -
6
Inhibition of the phosphatidylinositol 3-kinase-Akt pathway enhances gamma-2 herpesvirus lytic replication and facilitates reactivation from latency by Peng, Li, Wu, Ting-Ting, Tchieu, Jason H., Feng, Jun, Brown, Helen J., Feng, Jiaying, Li, Xudong, Qi, Jing, Deng, Hongyu, Vivanco, Igor, Mellinghoff, Ingo K., Jamieson, Christina, Sun, Ren
Published 2010Text -
7
Glucose deprivation activates a metabolic and signaling amplification loop leading to cell death by Graham, Nicholas A, Tahmasian, Martik, Kohli, Bitika, Komisopoulou, Evangelia, Zhu, Maggie, Vivanco, Igor, Teitell, Michael A, Wu, Hong, Ribas, Antoni, Lo, Roger S, Mellinghoff, Ingo K, Mischel, Paul S, Graeber, Thomas G
Published 2012Text -
8
STEAP: A prostate-specific cell-surface antigen highly expressed in human prostate tumors by Hubert, Rene S., Vivanco, Igor, Chen, Emily, Rastegar, Shiva, Leong, Kahan, Mitchell, Steve C., Madraswala, Rashida, Zhou, Yanhong, Kuo, James, Raitano, Arthur B., Jakobovits, Aya, Saffran, Douglas C., Afar, Daniel E. H.
Published 1999Text -
9
Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer by Regales, Lucia, Gong, Yixuan, Shen, Ronglai, de Stanchina, Elisa, Vivanco, Igor, Goel, Aviva, Koutcher, Jason A., Spassova, Maria, Ouerfelli, Ouathek, Mellinghoff, Ingo K., Zakowski, Maureen F., Politi, Katerina A., Pao, William
Published 2009Text -
10
DUSP4 protects BRAF- and NRAS-mutant melanoma from oncogene overdose through modulation of MITF by Gutierrez-Prat, Nuria, Zuberer, Hedwig L, Mangano, Luca, Karimaddini, Zahra, Wolf, Luise, Tyanova, Stefka, Wellinger, Lisa C, Marbach, Daniel, Griesser, Vera, Pettazzoni, Piergiorgio, Bischoff, James R, Rohle, Daniel, Palladino, Chiara, Vivanco, Igor
Published 2022Text -
11
A systematic molecular and pharmacologic evaluation of AKT inhibitors reveals new insight into their biological activity by Kostaras, Eleftherios, Kaserer, Teresa, Lazaro, Glorianne, Heuss, Sara Farrah, Hussain, Aasia, Casado, Pedro, Hayes, Angela, Yandim, Cihangir, Palaskas, Nicolaos, Yu, Yi, Schwartz, Brian, Raynaud, Florence, Chung, Yuen-Li, Cutillas, Pedro R., Vivanco, Igor
Published 2020Text -
12
Preliminary evidence of antitumour activity of Ipatasertib (Ipat) and Atezolizumab (ATZ) in glioblastoma patients (pts) with PTEN loss from the Phase 1 Ice-CAP trial (NCT03673787) by Tiu, Crescens, Welsh, Liam, Jones, Timothy, Zachariou, Anna, Prout, Toby, Turner, Alison, Daly, Rob, Tunariu, Nina, Riisnaes, Ruth, Gurel, Bora, Crespo, Mateus, Carreira, Suzanne, Vivanco, Igor, Jenkins, Ben, Yap, Christina, Minchom, Anna, Banerji, Udai, deBono, Johann, Lopez, Juanita
Published 2021Text -
13
SCIDOT-08. CHILDREN’S BRAIN TUMOUR DRUG DELIVERY CONSORTIUM (CBTDDC) by Rahman, Ruman, Campbell, Emma, Brem, Henry, Pearl, Monica, Green, Jordan, Janowski, Miroslaw, Walczak, Piotr, Tyler, Betty, Warren, Katherine, Singleton, Will, Mullen, Alexander, Boyd, Marie, Veal, Gareth, Hargrave, Darren, van Vuurden, Dannis, Powell, Steven, Battaglia, Giuseppe, Vivanco, Igor, Al-Jamal, Khuloud, Walker, David
Published 2019Text -
14
EGFR feedback-inhibition by Ran-binding protein 6 is disrupted in cancer by Oldrini, Barbara, Hsieh, Wan-Ying, Erdjument-Bromage, Hediye, Codega, Paolo, Carro, Maria Stella, Curiel-García, Alvaro, Campos, Carl, Pourmaleki, Maryam, Grommes, Christian, Vivanco, Igor, Rohle, Daniel, Bielski, Craig M., Taylor, Barry S., Hollmann, Travis J., Rosenblum, Marc, Tempst, Paul, Blenis, John, Squatrito, Massimo, Mellinghoff, Ingo K.
Published 2017Text -
15
Somatic mutations of the Parkinson's disease–associated gene PARK2 in glioblastoma and other human malignancies by Veeriah, Selvaraju, Taylor, Barry S, Meng, Shasha, Fang, Fang, Yilmaz, Emrullah, Vivanco, Igor, Janakiraman, Manickam, Schultz, Nikolaus, Hanrahan, Aphrothiti J, Pao, William, Ladanyi, Marc, Sander, Chris, Heguy, Adriana, Holland, Eric C, Paty, Philip B, Mischel, Paul S, Liau, Linda, Cloughesy, Timothy F, Mellinghoff, Ingo K, Solit, David B, Chan, Timothy A
Published 2009Text -
16
RBTT-06. TESSA JOWELL BRAIN MATRIX STUDY: A BRITISH FEASIBILITY STUDY OF MOLECULAR STRATIFICATION AND TARGETED THERAPY TO OPTIMIZE THE CLINICAL MANAGEMENT OF PATIENTS WITH GLIOMA by Watts, Colin, Apps, John, Ansorg, Olaf, Savage, Josh, Fox, Richard, Chalmers, Anthony, Short, Susan C, Thompson, Gerard, Waldman, Adam, Capper, David, Hargrave, Darren, Brennan, Paul, Smith, Stuart, Ashkan, Keyoumars, Wykes, Victoria, Kurian, Kathreena, Jamal-Hanjani, Mariam, Swanton, Charles, Buckle, Peter, Bulbeck, Helen, Stead, Lucy F, Vivanco, Igor, Bowden, Sarah
Published 2019Text -
17
The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation by Vivanco, Igor, Rohle, Daniel, Versele, Matthias, Iwanami, Akio, Kuga, Daisuke, Oldrini, Barbara, Tanaka, Kazuhiro, Dang, Julie, Kubek, Sara, Palaskas, Nicolaos, Hsueh, Teli, Evans, Michael, Mulholland, David, Wolle, Daniel, Rajasekaran, Sigrid, Rajasekaran, Ayyappan, Liau, Linda M., Cloughesy, Timothy F., Dikic, Ivan, Brennan, Cameron, Wu, Hong, Mischel, Paul S., Perera, Timothy, Mellinghoff, Ingo K.
Published 2010Text -
18
The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers by Veeriah, Selvaraju, Brennan, Cameron, Meng, Shasha, Singh, Bhuvanesh, Fagin, James A., Solit, David B., Paty, Philip B., Rohle, Dan, Vivanco, Igor, Chmielecki, Juliann, Pao, William, Ladanyi, Marc, Gerald, William L., Liau, Linda, Cloughesy, Timothy C., Mischel, Paul S., Sander, Chris, Taylor, Barry, Schultz, Nikolaus, Major, John, Heguy, Adriana, Fang, Fang, Mellinghoff, Ingo K., Chan, Timothy A.
Published 2009Text -
19
EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers by Smyth, Elizabeth C, Vlachogiannis, Georgios, Hedayat, Somaieh, Harbery, Alice, Hulkki-Wilson, Sanna, Salati, Massimiliano, Kouvelakis, Kyriakos, Fernandez-Mateos, Javier, Cresswell, George D, Fontana, Elisa, Seidlitz, Therese, Peckitt, Clare, Hahne, Jens C, Lampis, Andrea, Begum, Ruwaida, Watkins, David, Rao, Sheela, Starling, Naureen, Waddell, Tom, Okines, Alicia, Crosby, Tom, Mansoor, Was, Wadsley, Jonathan, Middleton, Gary, Fassan, Matteo, Wotherspoon, Andrew, Braconi, Chiara, Chau, Ian, Vivanco, Igor, Sottoriva, Andrea, Stange, Daniel E, Cunningham, David, Valeri, Nicola
Published 2021Text -
20
Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma by Beroukhim, Rameen, Getz, Gad, Nghiemphu, Leia, Barretina, Jordi, Hsueh, Teli, Linhart, David, Vivanco, Igor, Lee, Jeffrey C., Huang, Julie H., Alexander, Sethu, Du, Jinyan, Kau, Tweeny, Thomas, Roman K., Shah, Kinjal, Soto, Horacio, Perner, Sven, Prensner, John, Debiasi, Ralph M., Demichelis, Francesca, Hatton, Charlie, Rubin, Mark A., Garraway, Levi A., Nelson, Stan F., Liau, Linda, Mischel, Paul S., Cloughesy, Tim F., Meyerson, Matthew, Golub, Todd A., Lander, Eric S., Mellinghoff, Ingo K., Sellers, William R.
Published 2007Text